Aadi Bioscience (AADI)
(Real Time Quote from BATS)
$1.47 USD
+0.02 (1.38%)
Updated Aug 16, 2024 02:42 PM ET
2-Buy of 5 2
D Value C Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AADI 1.47 +0.02(1.38%)
Will AADI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AADI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AADI
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates
Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates
AADI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
Other News for AADI
Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript
Aadi Bioscience, Inc. 2024 Q2 - Results - Earnings Call Presentation
Aadi Bioscience Inc (AADI) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth and ...
TD Cowen Reaffirms Their Buy Rating on Aadi Bioscience (AADI)
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update